A Study of IMR-687 in Subjects With Sickle Cell Disease

Summary

A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease

Timeline

Start

2020-08-13

Primary completion

2022-03-02

Completion

2022-05-04

Outcome

Outcome not reported

Stopped: “A recently conducted Interim analysis of IMR-SCD-301 demonstrated that while IMR-687 was generally well-tolerated, it failed to meet its primary efficacy endpoint. So, the sponsor has decided to discontinue this study.”

Drugs

Indications